5-苯基-N-(吡啶-2-基甲基)-2-(嘧啶-5-基)喹唑啉-4-胺作为一种强效I Kur抑制剂的发现。
Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor.
作者信息
Finlay Heather J, Johnson James A, Lloyd John L, Jiang Ji, Neels James, Gunaga Prashantha, Banerjee Abhisek, Dhondi Naveen, Chimalakonda Anjaneya, Mandlekar Sandhya, Conder Mary Lee, Sale Harinath, Xing Dezhi, Levesque Paul, Wexler Ruth R
机构信息
Departments of Discovery Chemistry, Biology, and Preclinical Candidate Optimization, Bristol-Myers Squibb, Research and Development , P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Departments of Discovery Chemistry, Biology, and Preclinical Candidate Optimization, Biocon Bristol-Myers Squibb Research Center (BBRC) , Bangalore 560099, India.
出版信息
ACS Med Chem Lett. 2016 Jun 9;7(9):831-4. doi: 10.1021/acsmedchemlett.6b00117. eCollection 2016 Sep 8.
Abstract
A new series of phenylquinazoline inhibitors of Kv 1.5 is disclosed. The series was optimized for Kv 1.5 potency, selectivity versus hERG, pharmacokinetic exposure, and pharmacodynamic potency. 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (13k) was identified as a potent and ion channel selective inhibitor with robust efficacy in the preclinical rat ventricular effective refractory period (VERP) model and the rabbit atrial effective refractory period (AERP) model.
摘要
公开了一系列新型Kv 1.5的苯基喹唑啉抑制剂。该系列针对Kv 1.5效力、对hERG的选择性、药代动力学暴露和药效学效力进行了优化。5-苯基-N-(吡啶-2-基甲基)-2-(嘧啶-5-基)喹唑啉-4-胺(13k)被鉴定为一种强效且离子通道选择性抑制剂，在临床前大鼠心室有效不应期(VERP)模型和兔心房有效不应期(AERP)模型中具有强大的疗效。
相似文献
1
Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor.5-苯基-N-(吡啶-2-基甲基)-2-(嘧啶-5-基)喹唑啉-4-胺作为一种强效I Kur抑制剂的发现。
ACS Med Chem Lett. 2016 Jun 9;7(9):831-4. doi: 10.1021/acsmedchemlett.6b00117. eCollection 2016 Sep 8.
2
Selective I Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide.用于心房颤动潜在治疗的选择性 I 抑制剂：优化苯基喹唑啉系列，得到临床候选药物 5-[5-苯基-4-(吡啶-2-基甲基氨基)喹唑啉-2-基]吡啶-3-磺酰胺。
J Med Chem. 2017 May 11;60(9):3795-3803. doi: 10.1021/acs.jmedchem.6b01889. Epub 2017 Apr 28.
3
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.发现（S）-5-（甲氧基甲基）-7-（1-甲基-1H-吲哚-2-基）-2-（三氟甲基）-4,7-二氢吡唑并[1,5-a]嘧啶-6-基）（（S）-2-（3-甲基异恶唑-5-基）吡咯烷-1-基）甲酮作为一种有效的和选择性的 I(Kur)抑制剂。
J Med Chem. 2012 Apr 12;55(7):3036-48. doi: 10.1021/jm201386u. Epub 2012 Mar 21.
4
Synthesis and Structure-Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl--(Pyridin-2-ylmethyl)Pyrazolo[1,5-]Pyrimidin-7-Amines.3-苯基-（吡啶-2-基甲基）吡唑并[1,5-a]嘧啶-7-胺的抗分枝杆菌活性的合成及其构效关系
Pharmaceuticals (Basel). 2022 Sep 8;15(9):1125. doi: 10.3390/ph15091125.
5
Rhenium tricarbonyl core complexes of thymidine and uridine derivatives.胸苷和尿苷衍生物的三羰基铼核心配合物
Inorg Chem. 2005 Apr 4;44(7):2198-209. doi: 10.1021/ic048301n.
6
Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.4-(2,3-二氢-1H-苯并[d]吡咯并[1,2-a]咪唑-7-基)-N-(5-(哌嗪-1-基甲基)吡啶-2-基)嘧啶-2-胺作为高效选择性细胞周期蛋白依赖性激酶4和6抑制剂的设计与合成以及构效关系研究
Bioorg Med Chem Lett. 2018 Mar 1;28(5):974-978. doi: 10.1016/j.bmcl.2017.12.068. Epub 2018 Jan 31.
7
Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.发现 N-苯基-4-(1H-吡咯-3-基)嘧啶-2-胺衍生物是有效的 Mnk2 抑制剂：设计、合成、SAR 分析以及体外抗白血病活性评价。
Med Chem. 2019;15(6):602-623. doi: 10.2174/1573406415666181219111511.
8
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.3-(3-(4-(1-氨基环丁基)苯基)-5-苯基-3H-咪唑并[4,5-b]吡啶-2-基)吡啶-2-胺（ARQ 092）的发现：一种口服生物可利用的、选择性且强效的变构AKT抑制剂。
J Med Chem. 2016 Jul 14;59(13):6455-69. doi: 10.1021/acs.jmedchem.6b00619. Epub 2016 Jun 29.
9
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.设计、合成及苯乙胺杂环类化合物作为 K(v)1.5 抑制剂的评价。
Bioorg Med Chem Lett. 2014 Jul 15;24(14):3018-22. doi: 10.1016/j.bmcl.2014.05.035. Epub 2014 May 20.
10
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.高效、选择性且口服生物可利用的4-噻唑-N-(吡啶-2-基)嘧啶-2-胺细胞周期蛋白依赖性激酶4和6抑制剂作为抗癌候选药物：设计、合成与评价
J Med Chem. 2017 Mar 9;60(5):1892-1915. doi: 10.1021/acs.jmedchem.6b01670. Epub 2017 Feb 16.
引用本文的文献
1
Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5.Kv1.5 型钾电流通道亚型小分子调节剂面临的挑战。
Biomolecules. 2019 Dec 19;10(1):10. doi: 10.3390/biom10010010.
本文引用的文献
1
Pseudosaccharin amines as potent and selective KV1.5 blockers.伪糖精胺作为强效且选择性的KV1.5阻滞剂。
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4983-4986. doi: 10.1016/j.bmcl.2015.02.066. Epub 2015 Mar 7.
2
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.设计、合成及苯乙胺杂环类化合物作为 K(v)1.5 抑制剂的评价。
Bioorg Med Chem Lett. 2014 Jul 15;24(14):3018-22. doi: 10.1016/j.bmcl.2014.05.035. Epub 2014 May 20.
3
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.全球心房颤动流行病学：2010 年全球疾病负担研究。
Circulation. 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119. Epub 2013 Dec 17.
4
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.口服抗凝药和抗血小板药物治疗心房颤动结局试验的评价。
Europace. 2012 Mar;14(3):312-24. doi: 10.1093/europace/eur263.
5
Antiarrhythmic drug therapy for atrial fibrillation.心房颤动的抗心律失常药物治疗
Circulation. 2012 Jan 17;125(2):381-9. doi: 10.1161/CIRCULATIONAHA.111.019927.
6
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.吡咯烷酰胺基吡唑并二氢嘧啶作为有效且选择性的 Kv1.5 阻断剂。
Bioorg Med Chem Lett. 2010 Feb 15;20(4):1436-9. doi: 10.1016/j.bmcl.2009.12.085. Epub 2010 Jan 4.
7
Effect of dronedarone on cardiovascular events in atrial fibrillation.决奈达隆对房颤心血管事件的影响。
N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778.
8
New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.靶向心脏超快速延迟整流电流（I Kur）的新型药物：原理、药理学及潜在治疗价值的证据
J Cardiovasc Pharmacol. 2008 Aug;52(2):105-20. doi: 10.1097/FJC.0b013e3181719b0c.
9
The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.麻醉甲氧明致敏兔尖端扭转型室速模型
Pharmacol Ther. 2008 Aug;119(2):160-7. doi: 10.1016/j.pharmthera.2008.04.004. Epub 2008 May 16.
10
A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells.一种用于检测和表征哺乳动物细胞中钾通道调节剂的基于铊敏感性和荧光的检测方法。
J Biomol Screen. 2004 Dec;9(8):671-7. doi: 10.1177/1087057104268749.
Zotero 插件